Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
about
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesDistinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsTargeted killing of virally infected cells by radiolabeled antibodies to viral proteinsPre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradicationHIV-1 gp41 and gp160 are hyperthermostable proteins in a mesophilic environment. Characterization of gp41 mutants.Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complexAntibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityGenetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrumTruncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesIdentification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable regionCross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialEpitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloProspects for an HIV vaccine: conventional approaches and DNA immunization.Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjectsDynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infectionA broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchProduction and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Strategies for eliciting HIV-1 inhibitory antibodies
P2860
Q27318508-EAAF612B-FBF9-41B0-A544-391D800B2E17Q27469855-CA1F119C-4407-439C-A88A-B809BAFB426DQ27485578-A5FF635E-BD85-4EDA-9943-846FB009FF5DQ27665884-1D17BFEF-BA84-4F8C-B569-4231BE29478DQ27677941-D4E073F7-2278-4389-895D-776BBD4A7F6BQ28469068-DAB7EFC2-0F71-42A2-9211-52C6C0BB1D70Q28731318-E8561CF2-9306-43AF-8BE6-039CA651A597Q30341167-F9861131-E832-4788-951B-62A159CBFA6EQ30358769-831115DC-369D-4638-8F7C-52450453142FQ30453272-3CA08413-A4B8-4F17-B79C-F121932923CAQ30843874-0DB14FB1-9BA3-4F11-AAC9-632D423CD342Q33725718-CBD71625-80E1-455C-B2BD-203CB7567BDBQ33787329-73FCE4D1-B717-4B69-A926-41EC7E112C64Q33826951-2A4BC90A-6887-4772-95EB-78990166AC45Q33842152-83EF47E8-C9B4-44A0-9A1F-C9004238EA0DQ33853226-B84C1069-9B22-4C2B-8F57-78140B75588DQ34083235-898E7596-7C78-41A3-8E57-74371575620FQ34085098-C4117941-266E-463F-AFFE-2915563F319DQ34145199-89E124A3-B2DA-4EDD-8B12-6F7346540816Q34280115-840DE4CD-E32B-4415-BD78-EA238F624367Q34332519-16F850B7-6C08-48A6-A5CB-005A31C803C9Q34359035-24527526-6C3C-4011-B5B0-3959FAB232E9Q34374835-78827296-0CAB-4002-B727-1CB2AD54FF33Q34392963-79BE4BCB-2A69-44B6-8C82-76C5726B98A1Q34406977-A8E8038C-FE85-444A-B16B-1092CA172319Q34432690-B3E1FA97-B3C3-4148-BA7D-427C5B124B8BQ34471760-57195346-498D-4051-9A5E-4E58891A13ACQ34543052-928F506F-D7E6-451A-8532-9A1CDCDFC779Q34562259-D35FD82F-972A-4A5E-AEAE-74F159F82A78Q34907398-3760E62A-E49F-4F3B-A6B0-96B781B54267Q34948847-08790A72-26C3-4BAD-A0B9-5D90C502D255Q35024202-8AB9A770-7D13-4E65-BEBD-CBD8E47F6569Q35042496-A4706762-5C52-4E5D-A544-CD12DEB48E27Q35154909-D3BC36D3-709D-445F-9555-2A83F1EA050AQ35363127-CA868F41-48EB-4A28-A3FA-B9017E7797EDQ35706462-64B732EF-0D94-4261-8DE2-2ADE8034B582Q35817106-0464DEA5-90A5-4E88-B1D5-8DD36870A228Q35861256-1E69F902-6C65-4D2E-9176-A5FA266ACE55Q36384117-4A052528-CB21-4641-A6C8-A2358B468FE2Q36452155-6A23F24B-1C51-40B1-8200-29A22190274B
P2860
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Conserved and exposed epitopes ...... rus type 1 virions of group M.
@ast
Conserved and exposed epitopes ...... rus type 1 virions of group M.
@en
type
label
Conserved and exposed epitopes ...... rus type 1 virions of group M.
@ast
Conserved and exposed epitopes ...... rus type 1 virions of group M.
@en
prefLabel
Conserved and exposed epitopes ...... rus type 1 virions of group M.
@ast
Conserved and exposed epitopes ...... rus type 1 virions of group M.
@en
P2093
P2860
P1433
P1476
Conserved and exposed epitopes ...... irus type 1 virions of group M
@en
P2093
P2860
P304
P356
10.1128/JVI.74.15.7096-7107.2000
P577
2000-08-01T00:00:00Z